ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, we first discovered that this compound could obviously inhibit the proliferation of BCR-ABL + CML K562 cells at 0.1 μM, 0.33 μM, and 1 μM after 24 h exposure (P < 0.01, respectively; Figure 1(b)).